Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092935 · ClinicalTrials.gov registry record · Phase 2
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase 2 study, sponsored by Summit Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02092935 is a Phase 2 study that has completed, run by Summit Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT02092935, a Phase 2 study, has completed, sponsored by Summit Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and effectiveness of a new oral antibiotic called SMT19969 in treating C. difficile Infection (CDI).
Interventions
- DRUG Vancomycin
- DRUG SMT19969
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092935
The ClinicalTrials.gov registry entry for NCT02092935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT02092935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02092935 about?
NCT02092935 is a clinical study titled "A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)". The purpose of this research study is to evaluate the safety and effectiveness of a new oral antibiotic called SMT19969 in treating C. difficile Infection (CDI).
What is the current status of trial NCT02092935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02092935?
The interventions under investigation include: Vancomycin (DRUG), SMT19969 (DRUG).
Who is sponsoring clinical trial NCT02092935?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.